<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; HT Screening</title>
	<atom:link href="http://www.bioscreening.net/category/news/ht-screening/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Nigeria: FG and Cost of Cancer Screening</title>
		<link>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/</link>
		<comments>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 18:03:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Africa]]></category>
		<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1352</guid>
		<description><![CDATA[THE Federal Government&#8217;s recent directive to its hospitals to reduce the cost of cancer screening, though very commendable, is long overdue, considering that late diagnosis of the disease has resulted in the high rate of cancer related deaths in the country. Cancer is one of the leading causes of deaths in the world, especially in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NMR Fine-Tuned for High-Content Metabolomics Screening</title>
		<link>http://www.bioscreening.net/2011/11/28/nmr-fine-tuned-for-high-content-metabolomics-screening/</link>
		<comments>http://www.bioscreening.net/2011/11/28/nmr-fine-tuned-for-high-content-metabolomics-screening/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 17:48:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1350</guid>
		<description><![CDATA[Scientists report on the development of a nuclear magnetic resonance (NMR)-based method forscreening the metabolomic response of drug-treated mammalian cells to drug therapy. TheSanford-Burnham Medical Research Institute, and Rady Children’s Hospital investigators, say the highly sensitive, fast, and simple method is carried out in 96-well format, and could have particular utility as a method for high-throughput [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/28/nmr-fine-tuned-for-high-content-metabolomics-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>University at Buffalo symposium on in silico methods, high throughput screening</title>
		<link>http://www.bioscreening.net/2010/10/11/university-at-buffalo-symposium-on-in-silico-methods-high-throughput-screening/</link>
		<comments>http://www.bioscreening.net/2010/10/11/university-at-buffalo-symposium-on-in-silico-methods-high-throughput-screening/#comments</comments>
		<pubDate>Mon, 11 Oct 2010 13:55:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1042</guid>
		<description><![CDATA[BUFFALO, N.Y. &#8212; Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That&#8217;s the theme of a University at Buffalo symposium to be held Sept. 11 on &#8220;Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening,&#8221; which will feature a variety [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/10/11/university-at-buffalo-symposium-on-in-silico-methods-high-throughput-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Practical Approach to Quantitative High Throughput Screening</title>
		<link>http://www.bioscreening.net/2010/10/11/practical-approach-to-quantitative-high-throughput-screening/</link>
		<comments>http://www.bioscreening.net/2010/10/11/practical-approach-to-quantitative-high-throughput-screening/#comments</comments>
		<pubDate>Mon, 11 Oct 2010 13:50:40 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1038</guid>
		<description><![CDATA[Book: Chapter 18 Handbook of Drug Screening, Second Edition Ramakrishna Seethala and Litao Zhang Cover Image Published June 2009 ISBN 9781420061697 Edition Second Pages 504 Size 6 x 9 in Format Hardcover 142 illustrations * Online Chapter * Chapter PDF (431 KB) * * Reprints * Permissions Chapter Opening High throughput screening (HTS) has progressively [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/10/11/practical-approach-to-quantitative-high-throughput-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Virtual Screening</title>
		<link>http://www.bioscreening.net/2010/10/11/virtual-screening/</link>
		<comments>http://www.bioscreening.net/2010/10/11/virtual-screening/#comments</comments>
		<pubDate>Mon, 11 Oct 2010 13:46:16 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[HT Screening]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1036</guid>
		<description><![CDATA[1. Description 1. Virtual screening (VS) can be a useful alternative to HTS, especially if the assay will only permit a relatively small number of compounds to be tested. Different methods can be used depending on the information available. For any virtual screening, the selection of the database is as important as the methods used. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/10/11/virtual-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The NIH Molecular Libraries Program: Identifying Chemical Probes for New Medicines</title>
		<link>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/</link>
		<comments>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 18:12:01 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/</guid>
		<description><![CDATA[Alice McCarthy In 2003, several program leaders within theÂ National Institutes of Health (NIH) recognized that the results from the recently completed Human Genome Project were a launching pad for further study. Now that scientists knew the genome, how could they determine gene function? In particular, how could scientists find specific biological pathways and targets that [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/the-nih-molecular-libraries-program-identifying-chemical-probes-for-new-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Speeding up drug screening</title>
		<link>http://www.bioscreening.net/2010/07/12/915/</link>
		<comments>http://www.bioscreening.net/2010/07/12/915/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 14:28:39 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/915/</guid>
		<description><![CDATA[Box 1: Speeding up drug screening Whole-cell assays allow new drugs to be screened for efficacy without knowing the molecular targets. High-throughput screens (HTSs) are vital in the quest for new compounds, but until recently have been lacking for Chagas disease. At the Swiss Tropical and Public Health Institute, Reto Brun provides a &#8216;gold standard&#8217; [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/915/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NIH High-Throughput Screening Identifies Candidate Medicines for CMT</title>
		<link>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/</link>
		<comments>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:55:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/</guid>
		<description><![CDATA[The NIH has completed the high-throughput screening program. Working with a chemical library of more than 350,000 compounds, the NIH screened each compound at approximately 7 different dosage levels-resulting in more than 2 million unique screens. Out of the 4000 FDA approved drugs, 10 &#8220;hits&#8221; or candidate medicines were found. At this point in time, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/nih-high-throughput-screening-identifies-candidate-medicines-for-cmt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increased R&amp;D Efforts Are Overcoming Obstacles and Showing Potential</title>
		<link>http://www.bioscreening.net/2010/07/12/911/</link>
		<comments>http://www.bioscreening.net/2010/07/12/911/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 13:46:17 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/12/911/</guid>
		<description><![CDATA[Ion channels make good drug targetsâ€”they reside on the cell surface and are fast switching mechanisms. They act like cell transistors, controlling many cell processes. There are close to 500 types of ion channels, yet many remain undiscovered. This was mainly attributed to technology restraints, however, with the recent introduction of HT patch clamping, as [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/12/911/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanford-Burnham robots speed up path to discovery</title>
		<link>http://www.bioscreening.net/2010/07/08/sanford-burnham-robots-speed-up-path-to-discovery/</link>
		<comments>http://www.bioscreening.net/2010/07/08/sanford-burnham-robots-speed-up-path-to-discovery/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 02:40:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Education]]></category>
		<category><![CDATA[Equipment & Supplies]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/sanford-burnham-robots-speed-up-path-to-discovery/</guid>
		<description><![CDATA[The work force at Lake Nona&#8217;s Sanford- Burnham Institute includes 90 scientific staffers, 60 administrators and support personnel â€” and a team of three robots. The robots are part of a $15 million investment from the National Institutes of Health and occupy a large, glass-enclosed room on the bottom floor of Burnham&#8217;s Lake Nona campus. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/sanford-burnham-robots-speed-up-path-to-discovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Compound screening for drug development made simpler</title>
		<link>http://www.bioscreening.net/2010/05/13/compound-screening-for-drug-development-made-simpler/</link>
		<comments>http://www.bioscreening.net/2010/05/13/compound-screening-for-drug-development-made-simpler/#comments</comments>
		<pubDate>Thu, 13 May 2010 16:47:17 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/13/compound-screening-for-drug-development-made-simpler/</guid>
		<description><![CDATA[The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute&#8217;s medicinal chemistry group. Dr Jonathan Baell and Dr Georgina Holloway have developed a series of &#8216;filters&#8217; that can be used to weed out those molecules likely to come up as false [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/13/compound-screening-for-drug-development-made-simpler/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Throughput Screening 2010 Study Finds HTS Laboratories Using Effective Screening Strategies and Innovative Technologies to Increase Drug Discovery Success</title>
		<link>http://www.bioscreening.net/2010/05/13/high-throughput-screening-2010-study-finds-hts-laboratories-using-effective-screening-strategies-and-innovative-technologies-to-increase-drug-discovery-success/</link>
		<comments>http://www.bioscreening.net/2010/05/13/high-throughput-screening-2010-study-finds-hts-laboratories-using-effective-screening-strategies-and-innovative-technologies-to-increase-drug-discovery-success/#comments</comments>
		<pubDate>Thu, 13 May 2010 15:31:54 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/13/high-throughput-screening-2010-study-finds-hts-laboratories-using-effective-screening-strategies-and-innovative-technologies-to-increase-drug-discovery-success/</guid>
		<description><![CDATA[HTS laboratories are essential contributors to drug discovery, participating extensively in assay development and lead optimization as well as in primary and secondary screening of compound libraries. Effective screening strategies adopted by HTS laboratories include the use of more complex biological systems: more membrane-bound targets, more cell-based high content assays, and increased use of stem [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/13/high-throughput-screening-2010-study-finds-hts-laboratories-using-effective-screening-strategies-and-innovative-technologies-to-increase-drug-discovery-success/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evotec Signs High Throughput Screening Agreement With Active Biotech</title>
		<link>http://www.bioscreening.net/2010/05/13/evotec-signs-high-throughput-screening-agreement-with-active-biotech/</link>
		<comments>http://www.bioscreening.net/2010/05/13/evotec-signs-high-throughput-screening-agreement-with-active-biotech/#comments</comments>
		<pubDate>Thu, 13 May 2010 15:06:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/13/evotec-signs-high-throughput-screening-agreement-with-active-biotech/</guid>
		<description><![CDATA[Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a collaboration with Active Biotech AB (Stockholm:ACTI) to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay development, high throughput screening (HTS) and surface plasmon [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/13/evotec-signs-high-throughput-screening-agreement-with-active-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genentech and UCSFâ€™s Small Molecule Discovery Center Ink Deal Targeting Neurodegenerative Diseases</title>
		<link>http://www.bioscreening.net/2010/05/12/genentech-and-ucsf%e2%80%99s-small-molecule-discovery-center-ink-deal-targeting-neurodegenerative-diseases/</link>
		<comments>http://www.bioscreening.net/2010/05/12/genentech-and-ucsf%e2%80%99s-small-molecule-discovery-center-ink-deal-targeting-neurodegenerative-diseases/#comments</comments>
		<pubDate>Wed, 12 May 2010 18:26:30 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/12/genentech-and-ucsf%e2%80%99s-small-molecule-discovery-center-ink-deal-targeting-neurodegenerative-diseases/</guid>
		<description><![CDATA[The University of California, San Francisco and Genentech are partnering to discover and develop drug candidates for neurodegenerative diseases. The company will support the work of several researchers at the UCSF Small Molecule Discovery Center (SMDC) to progress prior SMDC research and Genentech discoveries. In addition to receiving financial support for its research function, UCSF [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/12/genentech-and-ucsf%e2%80%99s-small-molecule-discovery-center-ink-deal-targeting-neurodegenerative-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Emerald in the Rough</title>
		<link>http://www.bioscreening.net/2010/05/06/an-emerald-in-the-rough/</link>
		<comments>http://www.bioscreening.net/2010/05/06/an-emerald-in-the-rough/#comments</comments>
		<pubDate>Thu, 06 May 2010 19:10:46 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/06/an-emerald-in-the-rough/</guid>
		<description><![CDATA[Late last year, scientists at Emerald BioStructures, located on Bainbridge Island just across the Puget Sound from downtown Seattle, experienced the bittersweet ride that so often characterizes the drug discovery business. In August 2009, a team led by CEO Lance Stewart published a major paper outlining the application of a Fragments of Life (FOL) drug [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/06/an-emerald-in-the-rough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BellBrook Labs Launches a New Transcreener HTS Enzyme Assay</title>
		<link>http://www.bioscreening.net/2010/05/06/bellbrook-labs-launches-a-new-transcreener-hts-enzyme-assay/</link>
		<comments>http://www.bioscreening.net/2010/05/06/bellbrook-labs-launches-a-new-transcreener-hts-enzyme-assay/#comments</comments>
		<pubDate>Thu, 06 May 2010 15:26:21 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/06/bellbrook-labs-launches-a-new-transcreener-hts-enzyme-assay/</guid>
		<description><![CDATA[Madison, Wis. (PRWEB) January 11, 2010 &#8212; BellBrook Labs today announced that it has launched a new product in their proprietary Transcreener HTS Assay platform. The Transcreener GDP FI Assay was developed for detection of GTPases, a large family of enzymes that play diverse roles in normal and disease-related cell processes. The new assay overcomes [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/06/bellbrook-labs-launches-a-new-transcreener-hts-enzyme-assay/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies</title>
		<link>http://www.bioscreening.net/2010/05/06/genedata-at-hca-announces-banner-year-for-genedata-screener-at-leading-pharmaceutical-companies/</link>
		<comments>http://www.bioscreening.net/2010/05/06/genedata-at-hca-announces-banner-year-for-genedata-screener-at-leading-pharmaceutical-companies/#comments</comments>
		<pubDate>Thu, 06 May 2010 15:14:40 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/06/genedata-at-hca-announces-banner-year-for-genedata-screener-at-leading-pharmaceutical-companies/</guid>
		<description><![CDATA[7 out of the 25 top pharmas now use Genedata Screener for High Content Screening analysis. San Francisco, CA (PRWEB) January 11, 2010 &#8212; Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that over the past 12 months Genedata Screener has experienced unprecedented industry adoption with [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/06/genedata-at-hca-announces-banner-year-for-genedata-screener-at-leading-pharmaceutical-companies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Product Focus: Ultra-High-Throughput Screening</title>
		<link>http://www.bioscreening.net/2010/05/05/product-focus-ultra-high-throughput-screening/</link>
		<comments>http://www.bioscreening.net/2010/05/05/product-focus-ultra-high-throughput-screening/#comments</comments>
		<pubDate>Wed, 05 May 2010 21:14:12 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/05/product-focus-ultra-high-throughput-screening/</guid>
		<description><![CDATA[Ultra-high-throughput screening (uHTS) is an automation-based methodology for conducting hundreds of thousands of biological or chemical screening tests per day. The cutoff between high-throughput screening (HTS) and ultra-high-throughput is somewhat arbitrary. â€œThere is no fixed boundary,â€ says Simon Sheard, Ph.D., business development manager at RTS Life Science (Manchester, UK), which supplies automated sample management equipment [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/05/product-focus-ultra-high-throughput-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis &#8212; state of the art</title>
		<link>http://www.bioscreening.net/2010/05/05/focus-on-collagen-in-vitro-systems-to-study-fibrogenesis-and-antifibrosis-state-of-the-art/</link>
		<comments>http://www.bioscreening.net/2010/05/05/focus-on-collagen-in-vitro-systems-to-study-fibrogenesis-and-antifibrosis-state-of-the-art/#comments</comments>
		<pubDate>Wed, 05 May 2010 14:25:33 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/05/focus-on-collagen-in-vitro-systems-to-study-fibrogenesis-and-antifibrosis-state-of-the-art/</guid>
		<description><![CDATA[Fibrosis represents a major global disease burden, yet a potent antifibrotic compound is still not in sight. Part of the explanation for this situation is the difficulties that both academic laboratories and research and development departments in the pharmaceutical industry have been facing in re-enacting the fibrotic process in vitro for screening procedures prior to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/05/focus-on-collagen-in-vitro-systems-to-study-fibrogenesis-and-antifibrosis-state-of-the-art/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzyme binds both sides of the mirror</title>
		<link>http://www.bioscreening.net/2009/12/28/enzyme-binds-both-sides-of-the-mirror/</link>
		<comments>http://www.bioscreening.net/2009/12/28/enzyme-binds-both-sides-of-the-mirror/#comments</comments>
		<pubDate>Mon, 28 Dec 2009 15:30:16 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/28/enzyme-binds-both-sides-of-the-mirror/</guid>
		<description><![CDATA[European chemists have discovered that both mirror-image forms of a particular compound can bind at the same time in the same site of an enzyme, a phenomenon that has never been seen before. The finding has significance for drug discovery screening and studies of how small molecules interact with proteins. Rolf Breinbauer from Graz University [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/28/enzyme-binds-both-sides-of-the-mirror/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

